Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA)n Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?
Authors:
- Tristan M. SissungTSTristan M. Sissung
- Roberto H. BarbierRBRoberto H. Barbier
- Douglas K. PriceDPDouglas K. Price
- Teri M. PlonaTPTeri M. Plona
- Kristen M. PikeKPKristen M. Pike
- Stephanie D. MellottSMStephanie D. Mellott
- Ryan N. BaugherRBRyan N. Baugher
- Gordon R. WhiteleyGWGordon R. Whiteley
- Daniel R. SoppetDSDaniel R. Soppet
- David VenzonDVDavid Venzon
- Arlene BermanABArlene Berman
- Arun RajanARArun Rajan
Open Access
- 30 January 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (3) , 896
Abstract
To ensure accuracy of UGT1A1 (TA)n (rs3064744) genotyping for use in pharmacogenomics-based irinotecan dosing, we tested the concordance of several commonly used genotyping technologies. Heuristic genotype groupings and principal component analysis demonstrated concordance for Illumina sequencing, fragment analysis, and fluorescent PCR. However, Illumina sequencing and fragment analysis returned a range of fragment sizes, likely arising due to PCR “slippage”. Direct sequencing was accurate, but this method led to ambiguous electrophoregrams, hampering interpretation of heterozygotes. Gel sizing, pyrosequencing, and array-based technologies were less concordant. Pharmacoscan genotyping was concordant, but it does not ascertain (TA)8 genotypes that are common in African populations. Method-based genotyping differences were also observed in the publication record (p < 0.0046), although fragment analysis and direct sequencing were concordant (p = 0.11). Genotyping errors can have significant consequences in a clinical setting. At the present time, we recommend that all genotyping for this allele be conducted with fluorescent PCR (fPCR).Keywords
Funding Information
- National Institutes of Health (ZIA BC 010627)
This publication has 18 references indexed in Scilit:
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir PrescribingClinical Pharmacology & Therapeutics, 2015
- Pharmacogenomic Assessment of Mexican and Peruvian populationsPharmacogenomics, 2015
- The Genetic Ancestry of African Americans, Latinos, and European Americans across the United StatesThe American Journal of Human Genetics, 2015
- Development of Pyrosequencing Method for Detection of UGT1A1 Polymorphisms in Thai Colorectal CancersJournal of Clinical Laboratory Analysis, 2014
- Identifying Medication Misadventures: Poor Agreement Among Medical Record, Physician, Nurse, and Patient ReportsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010
- A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platformThe Pharmacogenomics Journal, 2009
- Rapid Allelic Discrimination by TaqMan PCR for the Detection of the Gilbert's Syndrome Marker UGT1A1*28The Journal of Molecular Diagnostics, 2008
- Pharmacogenetic Testing for Uridine Diphosphate Glucuronosyltransferase 1A1 Polymorphisms: Are We There Yet?Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008
- Comparison of three methods for genotyping the UGT1A1 (TA)n repeat polymorphismClinical Biochemistry, 2007
- UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and AsiansPharmacogenetics, 1999